Send to

Choose Destination
Oncotarget. 2018 Jun 12;9(45):27858-27871. doi: 10.18632/oncotarget.25559. eCollection 2018 Jun 12.

Interferon-stimulated gene 20 kDa protein serum levels and clinical outcome of hepatitis B virus-related liver diseases.

Van Tong H1,2,3, Hoan NX3,4,5, Binh MT3,4,5, Quyen DT3,4,5, Meyer CG3,5,6, Song LH4,5, Toan NL2, Velavan TP3,5,6.

Author information

Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam.
Department of Pathophysiology, Vietnam Military Medical University, Hanoi, Vietnam.
Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
108 Military Central Hospital, Hanoi, Vietnam.
Vietnamese-German Center of Excellence in Medical Research, Hanoi, Vietnam.
Duy Tan University, Da Nang, Vietnam.


Interferon-stimulated gene 20 kDa protein (ISG20) with 3' to 5' exonuclease activity mainly targeting single-stranded RNA plays an important role in immune responses against various infectious pathogens, including hepatitis viruses. ISG20 levels were measured by ELISA assays in sera of 339 hepatitis B-virus (HBV) infected patients and 71 healthy individuals and were correlated with clinical and laboratory parameters. ISG20 mRNA was quantified by qRT-PCR in 30 pairs of hepatocellular carcinoma (HCC) tumour and adjacent non-tumour liver tissues. ISG20 levels were significantly elevated in HBV patients compared to healthy controls (P<0.0001). In the patient group, varying ISG20 levels were associated with different forms of HBV-related liver diseases. ISG20 levels were higher in patients with HCC compared to those without HCC (P<0.0001), and increased according to the stages of HCC (P<0.0001). ISG20 mRNA expression was up-regulated in tumour tissues compared to the expression in adjacent non-tumour tissues (P=0.017). Importantly, ISG20 levels were strongly correlated with the levels of AST, ALT, total and direct bilirubin among HCC patients (Pearson's r = 0.43, 0.35, 0.34, 0.3; P<0.0001, respectively). Although differences between liver cirrhosis (LC) and non-LC patients were not observed, ISG20 levels were elevated according to the progression of cirrhosis in patients with LC plus HCC (P=0.005). In conclusions, ISG20 levels are induced by HBV infection and significantly associated with progression and clinical outcome of HBV-related liver diseases, especially in patients with HCC. ISG20 might be a potential indicator for liver injury and the clinical outcome in HBV-related HCC.


ISG20 expression; ISG20 levels; hepatocellular carcinoma; interferon-stimulated gene; viral hepatitis

Conflict of interest statement

CONFLICTS OF INTEREST All authors have no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center